SE0303179D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0303179D0
SE0303179D0 SE0303179A SE0303179A SE0303179D0 SE 0303179 D0 SE0303179 D0 SE 0303179D0 SE 0303179 A SE0303179 A SE 0303179A SE 0303179 A SE0303179 A SE 0303179A SE 0303179 D0 SE0303179 D0 SE 0303179D0
Authority
SE
Sweden
Prior art keywords
novel compounds
hfa
pmdis
suspensions
soluble
Prior art date
Application number
SE0303179A
Other languages
English (en)
Swedish (sv)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0303179A priority Critical patent/SE0303179D0/xx
Publication of SE0303179D0 publication Critical patent/SE0303179D0/xx
Priority to DE602004017783T priority patent/DE602004017783D1/de
Priority to EP04798662A priority patent/EP1708679B1/en
Priority to PT04798662T priority patent/PT1708679E/pt
Priority to AT04798662T priority patent/ATE413868T1/de
Priority to ES04798662T priority patent/ES2314469T3/es
Priority to BRPI0416992-1A priority patent/BRPI0416992A/pt
Priority to MXPA06005643A priority patent/MXPA06005643A/es
Priority to KR1020067010242A priority patent/KR20060118509A/ko
Priority to SI200430972T priority patent/SI1708679T1/sl
Priority to HK08102612.6A priority patent/HK1108390B/xx
Priority to NZ547355A priority patent/NZ547355A/en
Priority to PL04798662T priority patent/PL1708679T3/pl
Priority to US10/580,589 priority patent/US20070104652A1/en
Priority to PCT/GB2004/004957 priority patent/WO2005053637A2/en
Priority to CN200480040939A priority patent/CN100592908C/zh
Priority to AU2004294775A priority patent/AU2004294775B2/en
Priority to CA2546441A priority patent/CA2546441C/en
Priority to DK04798662T priority patent/DK1708679T3/da
Priority to JP2006540609A priority patent/JP4950666B2/ja
Priority to IL175659A priority patent/IL175659A/en
Priority to ZA200604330A priority patent/ZA200604330B/en
Priority to NO20062969A priority patent/NO20062969L/no
Priority to CY20091100063T priority patent/CY1108753T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SE0303179A 2003-11-26 2003-11-26 Novel compounds SE0303179D0 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
JP2006540609A JP4950666B2 (ja) 2003-11-26 2004-11-24 ハイドロフルオロアルカンおよびアシル化シクロデキストリンを含む医薬スプレー製剤
HK08102612.6A HK1108390B (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
PL04798662T PL1708679T3 (pl) 2003-11-26 2004-11-24 Farmaceutyczny preparat rozpyłowy zawierający hydrofluoroalkan i acylowaną cyklodekstrynę
PT04798662T PT1708679E (pt) 2003-11-26 2004-11-24 Formulação farmacêutica de vaporização compreendendo um hidrofluoralcano e uma ciclodextrina acilada
AT04798662T ATE413868T1 (de) 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin
ES04798662T ES2314469T3 (es) 2003-11-26 2004-11-24 Formulacion farmaceutica en aerosol que comprende un hidrofluoroalcano y una ciclodextrina acilada.
BRPI0416992-1A BRPI0416992A (pt) 2003-11-26 2004-11-24 novos compostos
MXPA06005643A MXPA06005643A (es) 2003-11-26 2004-11-24 Compuestos novedosos.
KR1020067010242A KR20060118509A (ko) 2003-11-26 2004-11-24 신규 화합물
SI200430972T SI1708679T1 (sl) 2003-11-26 2004-11-24 Farmacevtska pršilna formulacija, ki obsega hidrofluoroalkan in aciliran ciklodekstrin
DE602004017783T DE602004017783D1 (de) 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin
NZ547355A NZ547355A (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hydro fluoro alkane and an acylated cyclodextrin
EP04798662A EP1708679B1 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
US10/580,589 US20070104652A1 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
PCT/GB2004/004957 WO2005053637A2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin
CN200480040939A CN100592908C (zh) 2003-11-26 2004-11-24 包括氢氟烷和酰化环糊精的药用喷雾剂
AU2004294775A AU2004294775B2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin
CA2546441A CA2546441C (en) 2003-11-26 2004-11-24 Novel compounds
DK04798662T DK1708679T3 (da) 2003-11-26 2004-11-24 Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin
IL175659A IL175659A (en) 2003-11-26 2006-05-15 Pharmaceutical spray formulation comprising a hydrofluoroalkane and an acylated cyclodextrin
ZA200604330A ZA200604330B (en) 2003-11-26 2006-05-25 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
NO20062969A NO20062969L (no) 2003-11-26 2006-06-26 Nye forbindelser
CY20091100063T CY1108753T1 (el) 2003-11-26 2009-01-19 Φαρμακοτεχνικη μορφη σπρει που περιλαμβανει υδρο φθορο αλκανιο και μια ακυλιωμενη κυκλοδεξτρινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds

Publications (1)

Publication Number Publication Date
SE0303179D0 true SE0303179D0 (sv) 2003-11-26

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds

Country Status (23)

Country Link
US (1) US20070104652A1 (enExample)
EP (1) EP1708679B1 (enExample)
JP (1) JP4950666B2 (enExample)
KR (1) KR20060118509A (enExample)
CN (1) CN100592908C (enExample)
AT (1) ATE413868T1 (enExample)
AU (1) AU2004294775B2 (enExample)
BR (1) BRPI0416992A (enExample)
CA (1) CA2546441C (enExample)
CY (1) CY1108753T1 (enExample)
DE (1) DE602004017783D1 (enExample)
DK (1) DK1708679T3 (enExample)
ES (1) ES2314469T3 (enExample)
IL (1) IL175659A (enExample)
MX (1) MXPA06005643A (enExample)
NO (1) NO20062969L (enExample)
NZ (1) NZ547355A (enExample)
PL (1) PL1708679T3 (enExample)
PT (1) PT1708679E (enExample)
SE (1) SE0303179D0 (enExample)
SI (1) SI1708679T1 (enExample)
WO (1) WO2005053637A2 (enExample)
ZA (1) ZA200604330B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
JPWO2023127219A1 (enExample) * 2021-12-28 2023-07-06

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
AU2004294775B2 (en) 2007-12-20
ZA200604330B (en) 2007-11-28
HK1108390A1 (zh) 2008-05-09
US20070104652A1 (en) 2007-05-10
JP2007515401A (ja) 2007-06-14
PT1708679E (pt) 2008-12-29
NO20062969L (no) 2006-08-25
CY1108753T1 (el) 2014-04-09
JP4950666B2 (ja) 2012-06-13
WO2005053637A3 (en) 2007-06-28
CN101087600A (zh) 2007-12-12
CA2546441C (en) 2011-11-22
DE602004017783D1 (de) 2008-12-24
IL175659A (en) 2010-02-17
CA2546441A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
ES2314469T3 (es) 2009-03-16
ATE413868T1 (de) 2008-11-15
WO2005053637A2 (en) 2005-06-16
EP1708679B1 (en) 2008-11-12
CN100592908C (zh) 2010-03-03
IL175659A0 (en) 2006-09-05
SI1708679T1 (sl) 2009-04-30
BRPI0416992A (pt) 2007-02-06
PL1708679T3 (pl) 2009-04-30
NZ547355A (en) 2009-05-31
EP1708679A2 (en) 2006-10-11
AU2004294775A1 (en) 2005-06-16
MXPA06005643A (es) 2006-08-17
DK1708679T3 (da) 2009-02-16

Similar Documents

Publication Publication Date Title
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2004062613A3 (en) Hiv integrase inhibitors
MX2007005408A (es) Compuestos de aminoquinazolinas.
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
GB0119011D0 (en) Treatment of nail infections
NO20071095L (no) Hittil ukjente tiofenderivater
SG152292A1 (en) Pharmaceutical compositions
TW200513461A (en) Organische verbindungen
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
TW200801001A (en) Compounds
NO20032788L (no) Modafinil-forbindelse og cyklodekstrinblandinger
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
TW200716622A (en) Substituted piperidines
SI1688146T1 (sl) Priprava aldesleukina za farmacevtsko uporabo
TW200722424A (en) Substituted piperidines
MXPA06000987A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
GB0324210D0 (en) Organic compounds
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
ATE535251T1 (de) Stabile wässrige g-csf-haltige zusammensetzungen
SE0303179D0 (sv) Novel compounds
MX2007003398A (es) Sulfonamidas y sus usos.
TNSN05291A1 (en) Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
MX2007011381A (es) Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion.
WO2008036067A3 (en) Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
MXPA06000988A (es) Derivados de nicotinamida utiles como inhibidores de pde4.